Total: $73.29M | ||||
Company |
Location |
Amt. (M) |
Details |
Date |
Calypso Biotech |
Geneva |
€2.5 ($3.24) |
Calypso, a Merck Serono spinoff, received $3.24M in seed funding |
3/5/13 |
Carolus Therapeutics Inc. |
San Diego |
$2.25 |
Carolus received $2.25M in a debt facility from Square 1 Bank |
3/6/13 |
Dezima Pharma BV |
Naarden, the Netherlands |
€14.2 ($18.6) |
Dezima raised $18.6M, including €9.8M in a Series A round, and a €4.4M loan from Dutch Ministry of Economic Affairs agency Agentschap NL |
3/1/13 |
InteRNA Technologies BV |
Bilthoven, the Netherlands |
ND |
InteRNA closed an equity financing round, with participation from new investors Innovation and Investment Fund Gelderland and several angel investors |
3/27/13 |
Kala Pharmaceuticals Inc. |
Waltham, Mass. |
$11.5 |
Kala raised $11.5M in a Series A round through Crown Venture Fund LLC, joined by Lux Capital Management, Polaris Venture Partners and Third Rock Ventures |
3/1/13 |
Progenitor Labs Ltd. |
London |
£4 ($5.8) |
Progenitor raised $5.8M in seed financing from SR One's UK Fund |
3/12/13 |
Savara Pharmaceuticals Inc. |
Austin, Texas |
$7.4 |
Savara closed a $7.4M second tranche of a Series B financing, bringing the total raised to $16M |
3/21/13 |
TauRx Pharmaceuticals Ltd. |
Singapore |
$10.5 |
TauRx received an equity investment of $10.5M from Dundee Corp., of Toronto |
3/6/13 |
Theraclone Sciences Inc. |
Seattle |
$14 |
Theraclone raised $14M in a financing with existing investors ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures, Versant Ventures and Zenyaku Kogyo, which committed $8M; an additional $6M came from a credit facility with MidCap Financial and Silicon Valley Bank |
3/27/13 |
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. |